Indication
Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with metabolic dysfunction–associated steatohepatitis (MASH)* with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver.
This indication is approved based on improvement of MASH and liver scarring (fibrosis). There are ongoing studies to confirm the clinical benefit of Rezdiffra.
MASH was formerly called NASH (nonalcoholic steatohepatitis).
We use cookies to provide and improve our services. By using our site, you consent to cookies. Learn more.